同类适应症不同药物相同不良反应的住院费用比较
本研究在退伍军人健康管理局(VHA)数据中,采用校正广义线性模型比较同类适应症不同药物发生相同严重不良反应时的平均住院费用。总体费用无显著差异,但华法林相关胃肠道出血费用高于非甾体抗炎药,氯沙坦相关血管性水肿费用高于赖诺普利或赖诺普利/氢氯噻嗪。
要点
- 同类适应症药物发生相同不良反应时住院费用总体无显著差异。
- 华法林相关胃肠道出血住院费用高于非甾体抗炎药。
- 氯沙坦相关血管性水肿住院费用高于赖诺普利或赖诺普利/氢氯噻嗪。
核心结论
- 同类适应症不同药物发生相同不良反应时住院费用总体无显著差异,但特定药物-不良反应组合值得关注并考虑干预。
研究设计与样本
- 基于退伍军人健康管理局(VHA)数据的回顾性分析,采用校正广义线性模型(含Bonferroni多重比较校正及伽马分布)比较同类适应症不同药物相同不良反应的平均住院费用。
主要发现
- 华法林相关胃肠道出血的模型估计平均住院费用为18114美元(模型估计范围12522–26202美元),非甾体抗炎药为14255美元(估计范围9710–20929美元)。
- 氯沙坦相关血管性水肿的估计平均住院费用为14591美元(范围9467–22488美元),赖诺普利为8935美元(范围6301–12669美元),赖诺普利/氢氯噻嗪为8022美元(范围5424–11865美元)。
临床怎么用
- 临床可关注华法林相关胃肠道出血和氯沙坦相关血管性水肿的较高住院费用,考虑针对性干预以改善安全合理用药。
局限性
- 原文未明确报告研究样本量、研究时段及具体纳入排除标准等局限性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Costs of hospitalization due to severe adverse drug reactions (ADRs) were previously estimated within the Veterans Health Administration (VHA), but additional analyses are needed to infer potential interventions to mitigate these negative outcomes. The objective of this study was to compare specific adverse reaction-related hospitalization costs between medications with similar indications. METHODS: Mean hospitalization costs associated with the same ADR symptom were compared for different drugs with similar indications using adjusted generalized linear models with a Bonferroni correction for multiple comparisons as well as a gamma distribution. RESULTS: Overall, hospitalization costs between medications with similar indications were not significantly different for specific adverse reactions. However, gastrointestinal hemorrhage-associated costs were higher for warfarin versus nonsteroidal anti-inflammatory drugs (model estimate of mean cost, $18,114 [range of lower and upper model estimates, $12,522-$26,202] vs $14,255 [estimate range, $9,710-$20,929]). Similarly, the estimated mean hospitalization cost associated with angioedema was higher for losartan versus lisinopril or lisinopril/hydrochlorothiazide: $14,591 (range, $9467-$22,488) versus $8,935 (range, $6,301-$12,669) and $8,022 (range, $5,424-$11,865), respectively. CONCLUSION: Although we found few differences in the cost of hospitalization when comparing drugs with similar indications and the same adverse reaction, there were specific drug-ADR pairs that merit attention and consideration of interventions to improve safe and appropriate medication use. Evaluation of the effect of those interventions on the incidence of ADRs is an area for future study.
引用
- Alabbas SA, Jiang R, Au A, et al. Comparison of hospitalization costs for the same adverse reaction associated with different medications. Am J Health Syst Pharm. 2023. PMID: 36994836. doi:10.1093/ajhp/zxad060
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。